Cargando…
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
Superantigens activate T-cells by linking the T-cell receptor to MHC class II on antigen-presenting cells, and novel reactivity can be introduced by fusing the superantigen to a targeting molecule. Thus, an antibody-targeted superantigen, which activates T cells to destroy tumour cells, might be use...
Autores principales: | Forsberg, G, Ohlsson, L, Brodin, T, Björk, P, Lando, P A, Shaw, D, Stern, P L, Dohlsten, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363924/ https://www.ncbi.nlm.nih.gov/pubmed/11437414 http://dx.doi.org/10.1054/bjoc.2001.1891 |
Ejemplares similares
-
The distinct role of CD4(+) and CD8(+) T-cells during the anti-tumour effects of targeted superantigens
por: Litton, M J, et al.
Publicado: (1999) -
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma
por: Shaw, D M, et al.
Publicado: (2007) -
Editorial: Understanding and Engineering Antibody-Superantigen Interactions
por: Gan, Samuel Ken-En, et al.
Publicado: (2022) -
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens
por: Brodin, Petter, et al.
Publicado: (2022) -
Serum p53 antibodies: predictors of survival in small-cell lung cancer?
por: Murray, P V, et al.
Publicado: (2000)